Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Oncol.

Sec. Breast Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1662132

Primary Breast Leiomyosarcoma: Prognostic Factors and Treatment Outcomes – A Systematic Review and Case Report (1969–2023)

Provisionally accepted
Weiwei  ZhangWeiwei Zhang1,2*Rui  GuoRui Guo1,2Ji  XingliJi Xingli2Xiaohu  LiuXiaohu Liu2Lang  HeLang He2
  • 1Chengdu Fifth People's Hospital, Chengdu, China
  • 2The First Affiliated Hospital of Traditional Chinese Medicine of Chengdu Medical College, Chengdu, China

The final, formatted version of the article will be published soon.

Objective: This study aims to investigate the prognostic factors and treatment outcomes of primary breast leiomyosarcoma (PBL). We present a contemporary case of postoperative recurrence and metastasis, and conduct a systematic review to comprehensively analyze all reported cases over the past 54 years. Method: We describe a 48-year-old female with primary breast leiomyosarcoma managed with multimodal therapy, including surgery, chemotherapy, radiotherapy, and immunotherapy. Additionally, a systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched multiple electronic databases for studies on PBL published between 1969 and 2023. Patient demographics, clinical characteristics, and treatment strategies were extracted from the eligible studies. Kaplan-Meier survival analysis was employed to assess overall survival (OS), and Cox proportional hazards regression models were used to evaluate prognostic factors, including age, tumor size, and treatment approach. Result: The systematic search identified 98 eligible studies, which collectively reported on 106 patients with PBL. The PRISMA 2020 flow diagram illustrated the study selection process. Among the patients, 86.8% were female, and 50.9% of tumors originated in the left breast. The mean pretreatment tumor diameter was 6.38 ± 4.98 cm. Surgical intervention was performed in 88.1% of cases, predominantly mastectomy. Survival analysis revealed a median OS of 18 months. Subgroup analysis demonstrated significantly shorter OS in patients aged ≤37 years at diagnosis or with tumors >7 cm (P<0.05). Multivariate Cox regression identified younger age at diagnosis as an independent predictor of poor prognosis (HR: 4.514, 95% CI: 1.146-17.784, P = 0.031). Conclusion: Surgical resection remains the cornerstone of treatment for PBL. Our findings, derived from a PRISMA-guided systematic review, highlight younger age at diagnosis as a significant adverse prognostic factor, underscoring the need for tailored therapeutic strategies for this high-risk subgroup.

Keywords: Breast leiomyosarcoma, Breast sarcoma, prognosis, overall survival, tumor size

Received: 10 Jul 2025; Accepted: 14 Oct 2025.

Copyright: © 2025 Zhang, Guo, Xingli, Liu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Weiwei Zhang, zwwei89@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.